More on Andrew leach holding 25m shares just over 5%27 Oct 2023 06:31
ANDREW LEACH
Head of Chemical Biology and Head of Industry Partnerships at the European Bioinformatics Institute (EMBL-EBI)
Andrew studied Chemistry as an undergraduate and postgraduate at the University of Oxford and was an SERC/NATO post-doctoral fellow at the University of California, San Francisco. After three years at the University of Southampton he joined Glaxo/GlaxoSmithKline where over more than 20 years he was involved in the development and application of new platform capabilities for drug discovery in areas including computational chemistry and cheminformatics, fragment-based drug discovery, cardiovascular safety, proteomics and biological mass spectrometry. He also contributed to therapeutic projects and led GSK’s early Discovery portfolios against protease, ion channel and epigenetic targets. At EMBL-EBI he is responsible for a number of widely-used resources including ChEMBL, SureChEMBL, UniChem and ChEBI. His group is also involved in various international collaborations and consortia including Open Targets, Illuminating the Druggable Genome and EUbOPEN. His industry team works with the many commercial organisations and companies that make extensive use of the EBI's resources. Question is why would someone with his caliber connections in the industry want just over 5% of APTA .We know we have also just had director buys and Nickolas slater also buying into the company of late .Yesterday on the companys twitter page we got this . We are working in partnership with Bio-Works Technologies to develop new Optimer-based resins to improve the manufacture of viral vectors to support the continued rise in gene therapies. Back in June we also got this r RNS ptamer Group has successfully developed a panel of Optimer binders to a novel Alzheimer's disease biomarker. The Optimer binders have been patented by partners at Neuro-Bio, following the demonstration of performance in specifically binding to the target biomarker and functionality in a nasal mucous matrix. Further integration of the binders into a routine lateral flow test will support the clinical and commercial development of rapid diagnostics for Alzheimer's disease via simple nasal sampling, with the potential to diagnose the disease as early as 10-20 years before symptoms emerge. We also have had small contract RNS ..To me on a personal note dont you think something big is going on behind closed doors .These people think so or do they know so .
Sign In
Follow the stocks
